New York, August 5, 2020 (GLOBE NEWSWIRE) – Co-diagnostic-based saliva (NASDAQ: CODX) has replaced the game
Maxim reiterate Buy with a price target of $30
Earlier this week, Co-Diagnostics, Inc. (NASDAQ: CODX) (the company), a molecular diagnostics company with a patented diagnostic verification platform, announced that its partner, Clinical Reference Laboratory (CRL), one of the largest verification providers in the country, had obtained an FDA Emergency Use Authorization (U.S.) for a self-picked PCR control. Verification uses co-diagnostic probes and primers. CODX shares rose 28% in the news before watching the take profit on Tuesday.
The CRL indicated that the control demonstrated a 100 percent sensitivity/specificity (higher than any other saliva-based molecular control for COVID-19) and can be treated within 24 to 48 hours, which is vital given that in many cases, existing controls are on the way a week or more to return to the results.
Here are some highlights from the Maxim report:
Maxim’s full report can be found here.
Disclosure: Co-Diagnostics Inc. is one of BDA International.
About BDA International, Inc.:
Disclaimer
The information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained in this analysis reflect our current judgment and are subject to change without notice. We do not accept any responsibility or liability for any losses, damages or costs arising from an investor’s or other person’s reliance on or use of this analysis. This analysis is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities, nor a recommendation of any security, although members of the BDA may at times hold a position in the company covered within the article. Co-Diagnostics is a client of BDA International. Past gains are not a representative of future gains. The opinions herein contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. When used herein, the words “anticipate,” “intend,” “estimate,” “believe,” “expect,” “plans,” “should,” “potential,” “forecast,” and variations of such words and similar expressions are intended to identify forward-looking statements. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. A company’s actual results could differ materially from those described in any forward-looking statements contained herein. BDA is not a licensed broker, broker dealer, market maker, investment advisor, analyst or underwriter. We recommend that you use the information found herein as an initial starting point for conducting your own research in order to determine your own personal opinion of the companies discussed herein before deciding whether or not to invest. You should seek such investment, tax, financial, accounting or legal advice appropriate for your particular circumstances. Information about many publicly traded companies and other investor resources can be found at www.sec.gov. Investing in securities is speculative and carries risk.
Investor Relations Contact:Mushtaq Dost BDA International www.bda-ir.com